Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Liu, Peng; Zhao, Liwei; Pol, Jonathan; Lévesque, Sarah; Petrazzuolo, Adriana; Pfirschke, Christina; Engblom, Camilla; Rickelt, Steffen; Yamazaki, Takahiro; Iribarren, Kristina; Senovilla, Laura; Bezu, Lucillia; Vacchelli, Erika; Sica, Valentina; Melis, Andréa; Martin, Tiffany; Xia, Lin; Yang, Heng; Li, Qingqing; Chen, Jinfeng; Durand, Sylvère; Aprahamian, Fanny; Lefevre, Déborah; Broutin, Sophie; Paci, Angélo; Bongers, Amaury; Minard-Colin, Véronique; Tartour, Éric; Zitvogel, Laurence; Apétoh, Lionel; Ma, Yuting; J. Pittet, Mikaël; Kepp, Oliver; Kroemer, Guido

doi:10.1038/s41467-019-09415-3

Public

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Published in Nature Communications • Apr 2, 2019

Authors:

Peng Liu

Liwei Zhao

Jonathan Pol

Abstract

Immunogenic cell death (ICD) converts dying cancer cells into a therapeutic vaccine and stimulates antitumor immune responses. Here we unravel the results of an unbiased screen identifying high-dose (10 µM) crizotinib as an ICD-inducing tyrosine kinase inhibitor that has exceptional antineoplastic a...

Subject

Crizotinib

Cisplatin

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!